REVB

Conviction 52HealthcareScan · Mon, Aug 10, 2026

REVB$1.15+0.88%

ResistanceSupportVol 14

Vol MA14 21.61K

May 11May 28Jun 16Jul 6Jul 23Aug 10

REVELATION BIOSCIENCES, INC.PHARMACEUTICAL PREPARATIONSwww.revbiosciences.com ↗

Price1.15

Change+0.88%

Gap+6.14%

Rel volume0.03×

Avg volume40.82K

Avg $ vol44.51K

SMA 201.09

SMA 501.05

SMA 2001.11

Price vs 50+9.80%

Price vs 200+3.84%

MA stackmixed

50/200 cross—

Supertrenddown · 1.20

RSI (14)58

MACD hist0.01

MACD crossbull · 3d

Stoch %K / %D79 / 74

ADX (14)14

+DI / −DI22 / 24

RSI divergence—

MACD divergence—

ATR %+6.89%

ADR %7.43%

52w high2.93

52w low0.5230

From 52w high-60.75%

Above 52w low+119.89%

New 52w highNo

SqueezeOff

Bollinger width24.74%

%B0.73

Donchian pos74.64%

Donchian high1.23

Donchian low0.9293

AVWAP (52w high)1.11

vs AVWAP high+4.06%

AVWAP (52w low)1.29

vs AVWAP low-10.71%

OBV trendUp

Chaikin MF (20)-0.03

Today vs 20d0.03×

Avg vol (14d)21.61K

Avg vol (20d)40.82K

Avg $ vol (20d)44.51K

Market cap4.58M

RS 3m (vs SPY)+6.07%

RS 6m (vs SPY)-36.56%

RS line new highNo

Trend template5/8

Technical rank50.7

1 week+12.75%

1 month+15.00%

3 months+19.79%

6 months-30.30%

1 year-54.90%

YTD+41.42%

P/E-0.51

P/B0.46

P/S—

P/FCF-0.55

EPS-23.95

Div yield—

ROE-88.54%

ROA-71.32%

Debt/Eq—

Current6.21

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth40.73%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-6.9M

Revenue—

Net income-3.32M

Gross profit—

Free cash flow-8.29M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out3.91M

Employees9

ListedTue, Jan 11, 2022

Free float10.13M

Float %96.5%

Short interest20.2K

Days to cover0.3d

Short volume17.6%

Squeeze score2 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeC

Conviction52 / 100

Pattern quality—

Tech rank50.7 / 100

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.22

Support0.9396

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in REVB

All disclosures →

No recent disclosed trades by Congress in REVB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in REVB · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Zygmont Chester Stanley III Chief Financial Officer · Common Stock · 2026-04-30	Other	—	—	2026-04-30	2026-05-01
Rolke James Chief Executive Officer · Common Stock · 2026-04-30	Tax	10.12K	$11K	2026-04-30	2026-05-01
Zygmont Chester Stanley III Chief Financial Officer · Common Stock · 2026-04-30	Tax	13.29K	$15K	2026-04-30	2026-05-01

SEC filings

EDGAR filings in REVB · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.